266 related articles for article (PubMed ID: 28390139)
1. Effect of US Food and Drug Administration's Cardiovascular Safety Guidance on Diabetes Drug Development.
Hwang TJ; Franklin JM; Kesselheim AS
Clin Pharmacol Ther; 2017 Aug; 102(2):290-296. PubMed ID: 28390139
[TBL] [Abstract][Full Text] [Related]
2. FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later.
McGuire DK; Marx N; Johansen OE; Inzucchi SE; Rosenstock J; George JT
Diabetes Obes Metab; 2019 May; 21(5):1073-1078. PubMed ID: 30690856
[TBL] [Abstract][Full Text] [Related]
3. Should recent experiences with CVOTs for oral hypoglycemic drugs allow us to rethink the regulatory paradigm?
Meyer RJ
Clin Pharmacol Ther; 2015 Nov; 98(5):467-9. PubMed ID: 26234476
[TBL] [Abstract][Full Text] [Related]
4. Diabetes medications and cardiovascular outcome trials: Lessons learned.
Patel KV; de Albuquerque Rocha N; McGuire DK
Cleve Clin J Med; 2017 Oct; 84(10):759-767. PubMed ID: 28985176
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis.
Goyat R; Rai P; Chang J; Ponte CD; Tan X
Clin Drug Investig; 2018 Jun; 38(6):491-501. PubMed ID: 29564723
[TBL] [Abstract][Full Text] [Related]
6. An analysis of the impact of FDA's guidelines for addressing cardiovascular risk of drugs for type 2 diabetes on clinical development.
Viereck C; Boudes P
Contemp Clin Trials; 2011 May; 32(3):324-32. PubMed ID: 21266202
[TBL] [Abstract][Full Text] [Related]
7. Considerations for design and data analysis of noninferiority/superiority cardiovascular trials.
Quan H; Li M; Zhao PL; Cho M; Zhang J; Wu Y
J Biopharm Stat; 2013; 23(1):239-60. PubMed ID: 23331234
[TBL] [Abstract][Full Text] [Related]
8. Diabetes drugs pass cardiovascular risk check.
Opar A
Nat Rev Drug Discov; 2009 May; 8(5):343-4. PubMed ID: 19404302
[No Abstract] [Full Text] [Related]
9. Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?
Smith RJ; Goldfine AB; Hiatt WR
Diabetes Care; 2016 May; 39(5):738-42. PubMed ID: 27208377
[TBL] [Abstract][Full Text] [Related]
10. Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion.
Zannad F; Stough WG; Lipicky RJ; Tamargo J; Bakris GL; Borer JS; Alonso García Mde L; Hadjadj S; Koenig W; Kupfer S; McCullough PA; Mosenzon O; Pocock S; Scheen AJ; Sourij H; Van der Schueren B; Stahre C; White WB; Calvo G
Eur Heart J Cardiovasc Pharmacother; 2016 Jul; 2(3):200-5. PubMed ID: 27418973
[TBL] [Abstract][Full Text] [Related]
11. FDA reconsiders cardiovascular outcomes trials for diabetes drugs, 10 years on.
Mullard A
Nat Rev Drug Discov; 2018 Dec; 17(12):850-851. PubMed ID: 30443037
[No Abstract] [Full Text] [Related]
12. Impact of FDA guidance for developing diabetes drugs on trial design: from policy to practice.
Bethel MA; Sourij H
Curr Cardiol Rep; 2012 Feb; 14(1):59-69. PubMed ID: 22094711
[TBL] [Abstract][Full Text] [Related]
13. Innovative strategies for early clinical R&D.
Butz RF; Morelli G
IDrugs; 2008 Jan; 11(1):36-41. PubMed ID: 18175261
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive review of the FDA-approved labels of diabetes drugs: Indications, safety, and emerging cardiovascular safety data.
Gourgari E; Wilhelm EE; Hassanzadeh H; Aroda VR; Shoulson I
J Diabetes Complications; 2017 Dec; 31(12):1719-1727. PubMed ID: 28939018
[TBL] [Abstract][Full Text] [Related]
15. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
[TBL] [Abstract][Full Text] [Related]
16. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
17. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
Nat Rev Drug Discov; 2009 Feb; 8(2):99. PubMed ID: 19180100
[No Abstract] [Full Text] [Related]
18. Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus.
Hennekens CH; Hebert PR; Schneider WR; O'Brien P; Demets D; Borer JS
Contemp Clin Trials; 2010 Sep; 31(5):411-3. PubMed ID: 20601161
[TBL] [Abstract][Full Text] [Related]
19. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
20. Assessing the Safety of Glucose-Lowering Drugs - A New Focus for the FDA.
Chong WH; Yanoff LB; Andraca-Carrera E; Thanh Hai M
N Engl J Med; 2020 Sep; 383(13):1199-1202. PubMed ID: 32966719
[No Abstract] [Full Text] [Related]
[Next] [New Search]
